RAC Practice Exam 1 2025|Actual
Exam Set Questions And Verified
Answers (Correct solutions)With
rationales | Get It 100% Accurate!!
Save
Terms in this set (93)
,Which of the A.
following is NOT
required for
compliance
under 21 CFR Part
11 (electronic
records and
electronic
signatures)?
A Manually
generated
timestamped
audit trails to
record the date
and time of
operator entries
and actions that
create, modify or
delete electronic
records.
B Validation of
systems to ensure
accuracy
C Authority
checks to ensure
that only
authorized
,personell can
create, modify or
delete electronic
records.
D Establishment
of and adherence
to written
procedures
The final authority Institutional Review Board (IRB)
for ensuring the
adequacy of an
Investigational
New Drug (IND)
informed consent
document resides
with the:
, A sponsor wishes Suitability Petition
to obtain
permission from
FDA to submit an
ANDA for a drug
product that
varies from the
Reference Listed
Drug (RLD) in
route of
administration,
dosage form, or
strength, but
anticipates that
the labeling will
be identical to
that of the RLD.
What process
should be used
to apply for that
permission from
FDA?
Exam Set Questions And Verified
Answers (Correct solutions)With
rationales | Get It 100% Accurate!!
Save
Terms in this set (93)
,Which of the A.
following is NOT
required for
compliance
under 21 CFR Part
11 (electronic
records and
electronic
signatures)?
A Manually
generated
timestamped
audit trails to
record the date
and time of
operator entries
and actions that
create, modify or
delete electronic
records.
B Validation of
systems to ensure
accuracy
C Authority
checks to ensure
that only
authorized
,personell can
create, modify or
delete electronic
records.
D Establishment
of and adherence
to written
procedures
The final authority Institutional Review Board (IRB)
for ensuring the
adequacy of an
Investigational
New Drug (IND)
informed consent
document resides
with the:
, A sponsor wishes Suitability Petition
to obtain
permission from
FDA to submit an
ANDA for a drug
product that
varies from the
Reference Listed
Drug (RLD) in
route of
administration,
dosage form, or
strength, but
anticipates that
the labeling will
be identical to
that of the RLD.
What process
should be used
to apply for that
permission from
FDA?
